Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

Jean Luc Harousseau, Meletios A. Dimopoulos, Michael Wang, Alessandro Corso, Christine Chen, Michel Attal, Andrew Spencer, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert D. Knight, Donna M. Weber

Research output: Contribution to journalArticle

Abstract

Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. Design and Methods Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. Results At the time of unblinding, 32% of patients had achieved a complete or very good partial response and 28% had a partial response. Half (50.5%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P

Original languageEnglish
Pages (from-to)1738-1744
Number of pages7
JournalHaematologica
Volume95
Issue number10
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Multiple Myeloma
Dexamethasone
Survival
lenalidomide
Reaction Time
Therapeutics

Keywords

  • Clinical benefit
  • Dexamethasone
  • Efficacy
  • Lenalidomide
  • Multiple myeloma
  • Response

ASJC Scopus subject areas

  • Hematology

Cite this

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. / Harousseau, Jean Luc; Dimopoulos, Meletios A.; Wang, Michael; Corso, Alessandro; Chen, Christine; Attal, Michel; Spencer, Andrew; Yu, Zhinuan; Olesnyckyj, Marta; Zeldis, Jerome B.; Knight, Robert D.; Weber, Donna M.

In: Haematologica, Vol. 95, No. 10, 10.2010, p. 1738-1744.

Research output: Contribution to journalArticle

Harousseau, JL, Dimopoulos, MA, Wang, M, Corso, A, Chen, C, Attal, M, Spencer, A, Yu, Z, Olesnyckyj, M, Zeldis, JB, Knight, RD & Weber, DM 2010, 'Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma', Haematologica, vol. 95, no. 10, pp. 1738-1744. https://doi.org/10.3324/haematol.2009.015917
Harousseau, Jean Luc ; Dimopoulos, Meletios A. ; Wang, Michael ; Corso, Alessandro ; Chen, Christine ; Attal, Michel ; Spencer, Andrew ; Yu, Zhinuan ; Olesnyckyj, Marta ; Zeldis, Jerome B. ; Knight, Robert D. ; Weber, Donna M. / Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. In: Haematologica. 2010 ; Vol. 95, No. 10. pp. 1738-1744.
@article{42ce04db5dac4a51aa81e32f0d2e30c8,
title = "Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma",
abstract = "Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. Design and Methods Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. Results At the time of unblinding, 32{\%} of patients had achieved a complete or very good partial response and 28{\%} had a partial response. Half (50.5{\%}) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P",
keywords = "Clinical benefit, Dexamethasone, Efficacy, Lenalidomide, Multiple myeloma, Response",
author = "Harousseau, {Jean Luc} and Dimopoulos, {Meletios A.} and Michael Wang and Alessandro Corso and Christine Chen and Michel Attal and Andrew Spencer and Zhinuan Yu and Marta Olesnyckyj and Zeldis, {Jerome B.} and Knight, {Robert D.} and Weber, {Donna M.}",
year = "2010",
month = "10",
doi = "10.3324/haematol.2009.015917",
language = "English",
volume = "95",
pages = "1738--1744",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "10",

}

TY - JOUR

T1 - Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

AU - Harousseau, Jean Luc

AU - Dimopoulos, Meletios A.

AU - Wang, Michael

AU - Corso, Alessandro

AU - Chen, Christine

AU - Attal, Michel

AU - Spencer, Andrew

AU - Yu, Zhinuan

AU - Olesnyckyj, Marta

AU - Zeldis, Jerome B.

AU - Knight, Robert D.

AU - Weber, Donna M.

PY - 2010/10

Y1 - 2010/10

N2 - Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. Design and Methods Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. Results At the time of unblinding, 32% of patients had achieved a complete or very good partial response and 28% had a partial response. Half (50.5%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P

AB - Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. Design and Methods Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. Results At the time of unblinding, 32% of patients had achieved a complete or very good partial response and 28% had a partial response. Half (50.5%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P

KW - Clinical benefit

KW - Dexamethasone

KW - Efficacy

KW - Lenalidomide

KW - Multiple myeloma

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=77957774888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957774888&partnerID=8YFLogxK

U2 - 10.3324/haematol.2009.015917

DO - 10.3324/haematol.2009.015917

M3 - Article

C2 - 20460639

AN - SCOPUS:77957774888

VL - 95

SP - 1738

EP - 1744

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 10

ER -